Role of NF-κB in the skeleton

Cell Research

Volumn 21, Issue 1, 2011, Pages 169-182

  Novack, Deborah Veis ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

arthritis; chondrocyte; osteoblast; Osteoclast; osteoporosis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN SUBUNIT;

ANIMAL; BONE; CARTILAGE CELL; CYTOLOGY; METABOLISM; MOUSE; OSTEOBLAST; OSTEOCLAST; PHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; BONE AND BONES; CHONDROCYTES; MICE; NF-KAPPA B; OSTEOBLASTS; OSTEOCLASTS; PROTEIN SUBUNITS; SIGNAL TRANSDUCTION;

MUS;

EID: 78650858041     PISSN: 10010602     EISSN: 17487838     Source Type: Journal    
DOI: 10.1038/cr.2010.159     Document Type: Review

References (102)

1. Franzoso G, Carlson L, Xing L, et al. Requirement for NFκB in osteoclast and B-cell development. Genes Dev 1997; 11:3482-3496.
2. Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R. Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 1997; 3:1285-1289.
3. Ikeda F, Nishimura R, Matsubara T, et al. Critical roles of c-Jun signaling in regulation of NFAT family and RANKLregulated osteoclast differentiation. J Clin Invest 2004; 114:475-484.
4. Grigoriadis AE, Wang Z-Q, Cecchini MG, et al. c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science 1994; 266:443-448.
5. Novack DV, Faccio R. Osteoclast motility: Putting the brakes on bone resorption. Ageing Res Rev 2009 Sep 27; doi:10.1016/j.arr.2009.09.005.
6. Darnay BG, Haridas V, Ni J, Moore PA, Aggarwal BB. Characterization of the intracellular domain of receptor activator of NF-kappaB (RANK). Interaction with tumor necrosis factor receptor-associated factors and activation of NF-kappab and c-Jun N-terminal kinase. J Biol Chem 1998; 273:20551-20555.
7. Liu W, Xu D, Yang H, et al. Functional identification of three receptor activator of NF-κB cytoplasmic motifs mediating osteoclast differentiation and function. J Biol Chem 2004; 279:54759-54769.
8. Lamothe B, Webster WK, Gopinathan A, Besse A, Campos AD, Darnay BG. TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation. Biochem Biophys Res Commun 2007; 359:1044-1049.
9. Duran A, Serrano M, Leitges M, et al. The atypical PKCinteracting protein p62 is an important mediator of RANKactivated osteoclastogenesis. Dev Cell 2004; 6:303-309.
10. Jin W, Chang M, Paul EM, et al. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J Clin Invest 2008; 118:1858-1866.
11. Xing L, Carlson L, Story B, et al. Expression of either NFκB p50 or p52 in osteoclast precursors is required for IL-1- induced bone resorption. J Bone Miner Res 2003; 18:260-269.
12. Ruocco MG, Maeda S, Park JM, et al. IκB kinase (IKK)β but not IKKα, is a critical mediator of osteoclast survival and is required for inflammation-induced bone loss. J Exp Med 2005; 201:1677-1687.
13. Otero JE, Dai S, Foglia D, et al. Defective osteoclastogenesis by IKKα-null precursors is a result of receptor activator of NF-κB ligand (RANKL)-induced JNK-dependent apoptosis and impaired differentiation. J Biol Chem 2008; 283:24546-24553.
14. Jimi E, Aok K, Saito H, et al. Selective inhibition of NF-κB blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo. Nat Med 2004; 10:617-624.
15. Dai S, Hirayama T, Abbas S, Abu-Amer Y. The IκB Kinase (IKK) inhibitor, NEMO-binding domain peptide, blocks osteoclastogenesis and bone erosion in inflammatory arthritis. J Biol Chem 2004; 279:37219-37222.
16. Vaira S, Alhawagri M, Anwisye I, Kitaura H, Faccio R, Novack DV. RelA/p65 promotes osteoclast differentiation by blocking a RANKL-induced apoptotic JNK pathway in mice. J Clin Invest 2008; 118:2088-2097.
17. De Smaele E, Zazzeroni F, Papa S, et al. Induction of gadd45b by NF-kB downregulates pro-apoptotic JNK signalling. Nature 2001; 414:308-313.
18. Kamata H, Honda S, Maeda S, Chang L, Hirata H, Karin M. Reactive oxygen species promote TNFalpha-induced death and sustained JNK activation by inhibiting MAP kinase phosphatases. Cell 2005; 120:649-661.
19. Papa S, Zazzeroni F, Pham CG, Bubici C, Franzoso G. Linking JNK signaling to NF-κB: a key to survival. J Cell Sci 2004; 117:5197-5208.
20. Hauer J, Puschner S, Ramakrishnan P, et al. TNF receptor (TNFR)-associated factor (TRAF) 3 serves as an inhibitor of TRAF2/5-mediated activation of the noncanonical NF-κB pathway by TRAF-binding TNFRs. Proc Natl Acad Sci USA 2005; 102:2874-2879.
21. Novack DV, Yin L, Hagen-Stapleton A, et al. The IκB function of NF-κB2 p100 controls stimulated osteoclastogenesis. J Exp Med 2003; 198:771-781.
22. Vaira S, Johnson T, Hirbe AC, et al. RelB is the NF-κB subunit downstream of NIK responsible for osteoclast differentiation. Proc Natl Acad Sci USA 2008; 105:3897-3902.
23. Chaisson ML, Branstetter DG, Derry JM, et al. Osteoclast differentiation is impaired in the absence of inhibitor of κB kinase α. J Biol Chem 2004; 279:54841-54848.
24. Soysa NS, Alles N, Weih D, et al. The pivotal role of the alternative NF-κB pathway in maintenance of basal bone homeostasis and osteoclastogenesis. J Bone Miner Res 2010; 25:809-818.
25. Maruyama T, Fukushima H, Nakao K, et al. Processing of the NF-kappa B2 precursor p100 to p52 is critical for RANKL-induced osteoclast differentiation. J Bone Miner Res 2010; 25:1058-1067.
26. Solan NJ, Miyoshi H, Carmona EM, Bren GD, Paya CV. RelB cellular regulation and trancriptional activity are regulated by p100. J Biol Chem 2002; 277:1405-1418.
27. Otero JE, Dai S, Alhawagri MA, Darwech I, Abu-Amer Y. IKKα activation is sufficient for RANK-independent osteoclast differentiation and osteolysis. J Bone Miner Res 2010; 25:1282-1294.
28. Zou W, Hakim I, Tschoep K, Endres S, Bar-Shavit Z. Tumor necrosis factor-alpha mediates RANK ligand stimulation of osteoclast differentiation by an autocrine mechanism. J Cell Biochem 2001; 83:70-83.
29. Komine M, Kukita A, Kukita T, Ogata Y, Hotokebuchi T, Kohashi O. Tumor necrosis factor-α cooperates with receptor activator of nuclear factor κB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. Bone 2001; 28:474-483.
30. Lam J, Takeshita S, Barker JE, Kanagawa O, Ross FP, Teitelbaum SL. TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand. J Clin Invest 2000; 106:1481-1488.
31. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191:275-285.
32. Sabokbar A, Kudo O, Athanasou NA. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 2003; 21:73-80.
33. Azuma Y, Kaji K, Katogi R, Takeshita S, Kudo A. Tumor necrosis factor-α induces differentiation of and bone resorption by osteoclasts. J Biol Chem 2000; 275:4858-4864.
34. Yamashita T, Yao Z, Li F, et al. NF-κB p50 and p52 regulate receptor activator of NF-κB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 2007; 282:18245-18253.
35. Aya K, Alhawagri M, Hagen-Stapleton A, Kitaura H, Kanagawa O, Novack DV. NF-κB-inducing kinase controls lymphocyte and osteoclast activities in inflammatory arthritis. J Clin Invest 2005; 115:1848-1854.
36. Derudder E, Dejardin E, Pritchard LL, Green DR, Korner M, Baud V. RelB/p50 dimers are differentially regulated by tumor necrosis factor-{alpha} and lymphotoxin-{beta} receptor activation: CRITICAL ROLES FOR p100. J Biol Chem 2003; 278:23278-23284.
37. Yao Z, Xing L, Boyce BF. NF-kappaB p100 limits TNFinduced bone resorption in mice by a TRAF3-dependent mechanism. J Clin Invest 2009; 119:3024-3034.
38. Kitaura H, Sands MS, Aya K, et al. Marrow stromal cells and osteoclast precursors differentially contribute to TNF- α-induced osteoclastogenesis in vivo. J Immunol 2004; 173:4838-4846.
39. Jimi E, Hirata S, Shin M, Yamazaki M, Fukushima H. Molecular mechanisms of BMP-induced bone formation: crosstalk between BMP and NF-κB signaling pathways in osteoblastogenesis. Jpn Dent Sci Rev 2010; 46:33-42.
40. Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 2005; 288:E1011-1018.
41. Li Y, Li A, Strait K, Zhang H, Nanes MS, Weitzmann MN. Endogenous TNFα lowers maximum peak bone mass and inhibits osteoblastic Smad activation through NF-κB. J Bone Miner Res 2007; 22:646-655.
42. Eliseev RA, Schwarz EM, Zuscik MJ, O'Keefe RJ, Drissi H, Rosier RN. Smad7 mediates inhibition of Saos2 osteosarcoma cell differentiation by NFkappaB. Exp Cell Res 2006; 312:40-50.
43. Yamazaki M, Fukushima H, Shin M, et al. Tumor necrosis factor α represses bone morphogenetic protein (BMP) signaling by interfering with the DNA binding of Smads through the activation of NF-κB. J Biol Chem 2009; 284:35987-35995.
44. Lu X, Gilbert L, He X, Rubin J, Nanes MS. Transcriptional regulation of the osterix (Osx, Sp7) promoter by tumor necrosis factor identifies disparate effects of mitogen-activated protein kinase and NF kappa B pathways. J Biol Chem 2006; 281:6297-6306.
45. Chang J, Wang Z, Tang E, et al. Inhibition of osteoblastic bone formation by nuclear factor-κB. Nat Med 2009; 15:682-689.
46. Agarwal S, Long P, Seyedain A, Piesco N, Shree A, Gassner R. A central role for the nuclear factor-κB pathway in antiinflammatory and proinflammatory actions of mechanical strain. FASEB J 2003; 17:899-901.
47. Papachroni KK, Karatzas DN, Papavassiliou KA, Basdra EK, Papavassiliou AG. Mechanotransduction in osteoblast regulation and bone disease. Trends Mol Med 2009; 15:208-216.
48. Barron MJ, Tsai CJ, Donahue SW. Mechanical stimulation mediates gene expression in MC3T3 osteoblastic cells differently in 2D and 3D environments. J Biomech Eng 2010; 132:041005.
49. Young SR, Gerard-O'Riley R, Harrington M, Pavalko FM. Activation of NF-κB by fluid shear stress, but not TNF-α, requires focal adhesion kinase in osteoblasts. Bone 2010; 47:74-82.
50. Maruyama T, Fukushima H, Nakao K, et al. Processing of the NF-κB2 precursor p100 to p52 is critical for RANKLinduced osteoclast differentiation. J Bone Miner Res 2010; 25:1058-1067.
51. Tatsumi S, Ishii K, Amizuka N, et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 2007; 5:464-475.
52. Litzenberger J, Tang W, Castillo A, Jacobs C. Deletion of β1 integrins from cortical osteocytes reduces load-induced bone formation. Cell Mol Bioeng 2009; 2:416-424.
53. Genetos DC, Kephart CJ, Zhang Y, Yellowley CE, Donahue HJ. Oscillating fluid flow activation of gap junction hemichannels induces ATP release from MLO-Y4 osteocytes. J Cell Physiol 2007; 212:207-214.
54. Wu S, Flint JK, Rezvani G, De Luca F. Nuclear factor-κB p65 facilitates longitudinal bone growth by inducing growth plate chondrocyte proliferation and differentiation and by preventing apoptosis. J Biol Chem 2007; 282:33698-33706.
55. Wu S, Fadoju D, Rezvani G, De Luca F. Stimulatory effects of insulin-like growth factor-I on growth plate chondrogenesis are mediated by nuclear factor-κB p65. J Biol Chem 2008; 283:34037-34044.
56. Takeda K, Takeuchi O, Tsujimura T, et al. Limb and skin abnormalities in mice lacking IKKα. Science 1999; 284:313-316.
57. Li Q, Lu Q, Hwang JY, et al. IKK1-deficient mice exhibit abnormal development of skin and skeleton. Genes Dev 1999; 13:1322-1328.
58. Sil AK, Maeda S, Sano Y, Roop DR, Karin M. IκB kinase-α acts in the epidermis to control skeletal and craniofacial morphogenesis. Nature 2004; 428:660-664.
59. Simmonds RE, Foxwell BM. Signalling, inflammation and arthritis: NF-κB and its relevance to arthritis and inflammation. Rheumatology (Oxford) 2008; 47:584-590.
60. Clohisy JC, Roy BC, Biondo C, et al. Direct inhibition of NF-κB blocks bone erosion associated with inflammatory arthritis. J Immunol 2003; 171:5547-5553.
61. McIntyre KW, Shuster DJ, Gillooly KM, et al. A highly selective inhibitor of IκB kinase, BMS-345541, blocks both joint inflammation and destruction in collagen-induced arthritis in mice. Arthritis Rheum 2003; 48:2652-2659.
62. Jin W, Zhou XF, Yu J, Cheng X, Sun SC. Regulation of Th17 cell differentiation and EAE induction by MAP3K NIK. Blood 2009; 113:6603-6610.
63. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. Arthritis Rheum 2006; 54:3104-3112. (Pubitemid 44622079)
64. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFκB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 2006; 65:1495-1499.
65. Walsh NC, Reinwald S, Manning CA, et al. Osteoblast function is compromised at sites of focal bone erosion in inflammatory arthritis. J Bone Miner Res 2009; 24:1572-1585.
66. Schett G, Middleton S, Bolon B, et al. Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis models. Arthritis Rheum 2005; 52:1604-1611.
67. Walsh NC, Gravallese EM. Bone remodeling in rheumatic disease: a question of balance. Immunol Rev 2010; 233:301-312.
68. Wang P, Zhu F, Lee NH, Konstantopoulos K. Shear-induced interleukin-6 synthesis in chondrocytes: roles of E prostanoid (EP) 2 and EP3 in cAMP/protein kinase A- and PI3- K/Akt-dependent NF-kappaB activation. J Biol Chem 2010; 285:24793-24804.
69. Pulai JI, Chen H, Im HJ, et al. NF-kappa B mediates the stimulation of cytokine and chemokine expression by human articular chondrocytes in response to fibronectin fragments. J Immunol 2005; 174:5781-5788.
70. Chowdhury TT, Schulz RM, Rai SS, et al. Biomechanical modulation of collagen fragment-induced anabolic and catabolic activities in chondrocyte/agarose constructs. Arthritis Res Ther 2010; 12:R82.
71. Chevalier X, Goupille P, Beaulieu AD, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. Arthritis Rheum 2009; 61:344-352.
72. Magnano MD, Chakravarty EF, Broudy C, et al. A pilot study of tumor necrosis factor inhibition in erosive/inflammatory osteoarthritis of the hands. J Rheumatol 2007; 34:1323-1327.
73. Marcu KB, Otero M, Olivotto E, Borzi RM, Goldring MB. NF-κB signaling: multiple angles to target OA. Curr Drug Targets 2010; 11:599-613.
74. Sandell LJ, Xing X, Franz C, Davies S, Chang LW, Patra D. Exuberant expression of chemokine genes by adult human articular chondrocytes in response to IL-1beta. Osteoarthritis Cartilage 2008; 16:1560-1571.
75. Merz D, Liu R, Johnson K, Terkeltaub R. IL-8/CXCL8 and growth-related oncogene α/CXCL1 induce chondrocyte hypertrophic differentiation. J Immunol 2003; 171:4406-4415.
76. Chen LX, Lin L, Wang HJ, et al. Suppression of early experimental osteoarthritis by in vivo delivery of the adenoviral vector-mediated NF-κBp65-specific siRNA. Osteoarthritis Cartilage 2008; 16:174-184.
77. Nakamura T, Imai Y, Matsumoto T, et al. Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts. Cell 2007; 130:811-823.
78. Martin-Millan M, Almeida M, Ambrogini E, et al. The estrogen receptor-α in osteoclasts mediates the protective effects of estrogens on cancellous but not cortical bone. Mol Endocrinol 2010; 24:323-334.
79. Kalaitzidis D, Gilmore TD. Transcription factor cross-talk: the estrogen receptor and NF-κB. Trends Endocrinol Metab 2005; 16:46-52.
80. Frasor J, Weaver A, Pradhan M, et al. Positive cross-talk between estrogen receptor and NF-κB in breast cancer. Cancer Res 2009; 69:8918-8925.
81. Charatcharoenwitthaya N, Khosla S, Atkinson EJ, Mc- Cready LK, Riggs BL. Effect of blockade of TNF-α and interleukin-1 action on bone resorption in early postmenopausal women. J Bone Miner Res 2007; 22:724-729.
82. Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL. IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115:282-290.
83. Goode A, Layfield R. Recent advances in understanding the molecular basis of Paget disease of bone. J Clin Pathol 2010; 63:199-203.
84. Najat D, Garner T, Hagen T, et al. Characterization of a non-UBA domain missense mutation of sequestosome 1 (SQSTM1) in Paget's disease of bone. J Bone Miner Res 2009; 24:632-642.
85. Rea SL, Walsh JP, Ward L, et al. Sequestosome 1 mutations in Paget's disease of bone in Australia: prevalence, genotype/ phenotype correlation, and a novel non-UBA domain mutation (P364S) associated with increased NF-κB signaling without loss of ubiquitin binding. J Bone Miner Res 2009; 24:1216-1223.
86. Chamoux E, Couture J, Bisson M, Morissette J, Brown JP, Roux S. The p62 P392L mutation linked to Paget's disease induces activation of human osteoclasts. Mol Endocrinol 2009; 23:1668-1680.
87. Hiruma Y, Kurihara N, Subler MA, et al. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum Mol Genet 2008; 17:3708-3719.
88. Kurihara N, Zhou H, Reddy SV, et al. Experimental models of Paget's disease. J Bone Miner Res 2006; 21 Suppl 2:P55- 57.
89. Hirbe AC, Uluckan O, Morgan EA, et al. Granulocyte colo ny-stimulating factor enhances bone tumor growth in mice in an osteoclast-dependent manner. Blood 2007; 109:3424-3431.
90. Canon JR, Roudier M, Bryant R, et al. Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis. Clin Exp Metastasis 2008; 25:119-129.
91. Lipton A, Theriault RL, Hortobagyi GN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000; 88:1082-1090.
92. Lipton A, Steger GG, Figueroa J, et al. Randomized activecontrolled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J Clin Oncol 2007; 25:4431-4437.
93. Wang X, Belguise K, Kersual N, et al. Oestrogen signalling inhibits invasive phenotype by repressing RelB and its target BCL2. Nat Cell Biol 2007; 9:470-478.
94. Bakewell SJ, Nestor P, Prasad S, et al. Platelet and osteoclast β3 integrins are critical for bone metastasis. Proc Natl Acad Sci USA 2003; 100:14205-14210.
95. Hirbe AC, Roelofs AJ, Floyd DH, et al. The bisphosphonate zoledronic acid decreases tumor growth in bone in mice with defective osteoclasts. Bone 2009; 44:908-916.
96. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007; 12:115-130.
97. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-κB pathway in multiple myeloma. Cancer Cell 2007; 12:131-144.
98. von Metzler I, Krebbel H, Hecht M, et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21:2025-2034.
99. Hongming H, Jian H. Bortezomib inhibits maturation and function of osteoclasts from PBMCs of patients with multiple myeloma by downregulating TRAF6. Leuk Res 2009; 33:115-122.
100. Hideshima T, Chauhan D, Kiziltepe T, et al. Biologic sequelae of IκB kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood 2009; 113:5228-5236.
101. Jourdan M, Moreaux J, Vos JD, et al. Targeting NF-κB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth. Br J Haematol 2007; 138:160-168.
102. Markovina S, Callander NS, O'Connor SL, et al. Bortezomib- resistant nuclear factor-κB activity in multiple myeloma cells. Mol Cancer Res 2008; 6:1356-1364.